GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (BSP:N1VO34) » Definitions » E10

Novo Nordisk A/S (BSP:N1VO34) E10 : R$0.92 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Novo Nordisk A/S E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Novo Nordisk A/S's adjusted earnings per share data for the three months ended in Dec. 2023 was R$3.520. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is R$0.92 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Novo Nordisk A/S's average E10 Growth Rate was 15.40% per year. During the past 3 years, the average E10 Growth Rate was 14.20% per year. During the past 5 years, the average E10 Growth Rate was 13.00% per year. During the past 10 years, the average E10 Growth Rate was 14.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Novo Nordisk A/S was 27.70% per year. The lowest was 4.30% per year. And the median was 15.05% per year.

As of today (2024-04-28), Novo Nordisk A/S's current stock price is R$81.12. Novo Nordisk A/S's E10 for the quarter that ended in Dec. 2023 was R$0.92. Novo Nordisk A/S's Shiller PE Ratio of today is 88.17.

During the past 13 years, the highest Shiller PE Ratio of Novo Nordisk A/S was 88.29. The lowest was 25.12. And the median was 39.48.


Novo Nordisk A/S E10 Historical Data

The historical data trend for Novo Nordisk A/S's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S E10 Chart

Novo Nordisk A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.73 0.82 0.84 0.92

Novo Nordisk A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.84 0.86 0.84 0.89 0.92

Competitive Comparison of Novo Nordisk A/S's E10

For the Biotechnology subindustry, Novo Nordisk A/S's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk A/S's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novo Nordisk A/S's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Novo Nordisk A/S's Shiller PE Ratio falls into.



Novo Nordisk A/S E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novo Nordisk A/S's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=3.52/116.7000*116.7000
=3.520

Current CPI (Dec. 2023) = 116.7000.

Novo Nordisk A/S Quarterly Data

per share eps CPI Adj_EPS
201403 0.523 99.600 0.613
201406 0.542 99.700 0.634
201409 0.500 99.700 0.585
201412 0.549 99.400 0.645
201503 0.863 100.200 1.005
201506 0.756 100.300 0.880
201509 0.957 100.200 1.115
201512 0.917 99.800 1.072
201603 1.024 100.200 1.193
201606 1.013 100.600 1.175
201609 0.948 100.200 1.104
201612 0.823 100.300 0.958
201703 0.913 101.200 1.053
201706 0.998 101.200 1.151
201709 0.993 101.800 1.138
201712 0.880 101.300 1.014
201803 1.194 101.700 1.370
201806 1.259 102.300 1.436
201809 1.202 102.400 1.370
201812 1.045 102.100 1.194
201903 1.267 102.900 1.437
201906 1.175 102.900 1.333
201909 1.304 102.900 1.479
201912 1.129 102.900 1.280
202003 1.824 103.300 2.061
202006 1.775 103.200 2.007
202009 1.890 103.500 2.131
202012 1.687 103.400 1.904
202103 2.458 104.300 2.750
202106 2.143 105.000 2.382
202109 2.201 105.800 2.428
202112 2.045 106.600 2.239
202203 2.292 109.900 2.434
202206 2.101 113.600 2.158
202209 2.211 116.400 2.217
202212 2.248 115.900 2.264
202303 3.289 117.300 3.272
202306 3.048 116.400 3.056
202309 3.534 117.400 3.513
202312 3.520 116.700 3.520

Add all the adjusted EPS together and divide 10 will get our e10.


Novo Nordisk A/S  (BSP:N1VO34) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Novo Nordisk A/S's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=81.12/0.92
=88.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Novo Nordisk A/S was 88.29. The lowest was 25.12. And the median was 39.48.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Novo Nordisk A/S E10 Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk A/S (BSP:N1VO34) Business Description

Address
Novo Alle 1, Bagsvaerd, DNK, DK-2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk A/S (BSP:N1VO34) Headlines

No Headlines